All In MedTech

FDA Clearance Tracker · P110027-S012

therascreen KRAS RGQ PCR KIT

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: May 28, 2021 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

May 28, 2021

Approved

Time to decision

107 days

Received Feb 10, 2021. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Panel Track

Device class

Class III

The decision

FDA number
P110027-S012
Device name
therascreen KRAS RGQ PCR KIT
Applicant
QIAGEN GmbH
Applicant location
Hilden
Received
Feb 10, 2021
Decided
May 28, 2021
Decision
Approved
Supplement type
Panel Track
Reason for supplement
Labeling Change - Indications/instructions/shelf life/tradename
Original approval
P110027

Device type

Device class
Class III

Every decision under product code OWD

FDA's approval statement

As written in FDA's record.

Approval for expanding the indication to aid in the identification of non-small cell lung cancer patients whose tumors harbor KRAS G12C mutations and may benefit from treatment with LUMAKRA (sotorasib).

Source documents

Other decisions for QIAGEN GmbH

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.